EP0806484A3
Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses
Abstract
The invention relates to an oligonucleotide which can be used as a primer for the amplification of nucleic acid sequences, characterized in that its sequence is chosen from the conserved and specific sequences of the gag, vpr, pol or vpu genes of the HIV-1 viruses. 1 Bru, HIV-1 Mal, and HIV-1 Eli HIV-2 ROD and SIV MAC, or in the nef2, vif2 and vpx genes of the HIV-2 ROD and SIV MAC viruses, or among the complementary sequences thereof.
Term
Term ended
Projected expiry passed 5 June 2010, 16.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 5 of 6
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP0229701A2 | Cites | European Patent Office (EPO) | X | Search report | 1-4,11-24 |
| EP0269445A2 | Cites | European Patent Office (EPO) | Y | Search report | 1-4,11-24 |
| EP0269520A2 | Cites | European Patent Office (EPO) | Y | Search report | 1,18,20-23 |
| EP0272098A2 | Cites | European Patent Office (EPO) | Y | Search report | 1-4,11-24 |
| WO8805440A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1,18,20-23 |
| OU C-H ET AL: "DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells", SCIENCE, vol. 239, 15 January 1988 (1988-01-15), pages 295 - 297, XP002135449 | Non-patent | – | – | Search report | – |
| RAYFIELD M ET AL: "Mixed human immunodeficiency virus (HIV) infection in an individual: Demonstration of both HIV type 1 and 2 proviral sequences by using polymerase chain reaction", THE JOURNAL OF INFECTIOUS MEDICINE, vol. 158, no. 9, 6 December 1988 (1988-12-06), pages 1170 - 76, XP002135450 | Non-patent | – | – | Search report | – |
| KWOK S ET AL: "IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS SEQUENCES BY USING IN VITRO ENZYMATIC AMPLIFICATION AND OLIGOMER CLEAVAGE DETECTION", JOURNAL OF VIROLOGY,US,NEW YORK, US, vol. 61, no. 5, 1 May 1987 (1987-05-01), pages 1690 - 1694, XP000616284, ISSN: 0022-538X | Non-patent | – | – | Search report | – |
72 members in 13 offices
Priority claims14
| Document | Office | Kind | Date |
|---|---|---|---|
| 8907354 | France | A | |
| 8907354 | France | A | |
| 8907354 | France | – | |
| 8912371 | France | A | |
| 8912371 | France | A | |
| 8912371 | France | – | |
| 90401520 | European Patent Office (EPO) | A | |
| 90401520 | European Patent Office (EPO) | A | |
| 8907354 | – | – | – |
| 8912371 | – | – | – |
| 90401520 | – | – | – |
| EP19900401520 | – | – | – |
| FR19890007354 | – | – | – |
| FR19890012371 | – | – | – |
Members72
| Document | Office | Kind | |
|---|---|---|---|
| CA2062829A1 | Canada | A1 | |
| FR2647809A1 | France | A1 | |
| CA2585164A1 | Canada | A1 | |
| CA2685262A1 | Canada | A1 | |
| WO9015066A2 | World Intellectual Property Organization (WIPO) | A2 | |
| EP0403333A2 | European Patent Office (EPO) | A2 | |
| FR2652091A1 | France | A1 | |
| WO9015066A3 | World Intellectual Property Organization (WIPO) | A3 | |
| FR2647809B1 | France | B1 | |
| EP0403333A3 | European Patent Office (EPO) | A3 | |
| JPH04507043A | Japan | A | |
| FR2652091B1 | France | B1 | |
| EP0806484A2 | European Patent Office (EPO) | A2 | |
| US5688637A | United States of America | A | |
| SG47868A1 | Singapore | A1 | |
| US5786177A | United States of America | A | |
| EP0403333B1 | European Patent Office (EPO) | B1 | |
| AT185379T | Austria | T | |
| ATE185379T1 | Austria | T1 | |
| DE69033311D1 | Germany | D1 | |
| ES2139567T3 | Spain | T3 | |
| DE69033311T2 | Germany | T2 | |
| DK0403333T3 | Denmark | T3 | |
| JP2000093187A | Japan | A | |
| GR3032261T3 | Greece | T3 | |
| EP0806484A3This record | European Patent Office (EPO) | A3 | |
| US6194142B1 | United States of America | B1 | |
| JP3428012B2 | Japan | B2 | |
| US2005037340A1 | United States of America | A1 | |
| US2006035260A1 | United States of America | A1 | |
| US7022814B1 | United States of America | B1 | |
| EP1642987A2 | European Patent Office (EPO) | A2 | |
| EP0806484B1 | European Patent Office (EPO) | B1 | |
| AT323183T | Austria | T | |
| ATE323183T1 | Austria | T1 | |
| DE69034220D1 | Germany | D1 | |
| US7078516B1 | United States of America | B1 | |
| DK0806484T3 | Denmark | T3 | |
| EP1642987A3 | European Patent Office (EPO) | A3 | |
| EP1715064A1 | European Patent Office (EPO) | A1 | |
| ES2262166T3 | Spain | T3 | |
| DE69034220T2 | Germany | T2 | |
| HK1092839A1 | Hong Kong, China | A1 | |
| DE05014676T1 | Germany | T1 | |
| EP1715064A8 | European Patent Office (EPO) | A8 | |
| ES2275451T1 | Spain | T1 | |
| HK1097574A1 | Hong Kong, China | A1 | |
| CA2062829C | Canada | C | |
| EP1642987B1 | European Patent Office (EPO) | B1 | |
| AT404699T | Austria | T | |
| ATE404699T1 | Austria | T1 | |
| DE69034260D1 | Germany | D1 | |
| DK1642987T3 | Denmark | T3 | |
| EP2011888A1 | European Patent Office (EPO) | A1 | |
| ES2275451T3 | Spain | T3 | |
| EP1715064B1 | European Patent Office (EPO) | B1 | |
| AT423856T | Austria | T | |
| ATE423856T1 | Austria | T1 | |
| ES2315215T1 | Spain | T1 | |
| DE69034265D1 | Germany | D1 | |
| DE07025195T1 | Germany | T1 | |
| ES2321326T3 | Spain | T3 | |
| DK1715064T3 | Denmark | T3 | |
| HK1125136A1 | Hong Kong, China | A1 | |
| CA2585164C | Canada | C | |
| EP2011888B1 | European Patent Office (EPO) | B1 | |
| AT466111T | Austria | T | |
| ATE466111T1 | Austria | T1 | |
| DE69034267D1 | Germany | D1 | |
| US7759477B2 | United States of America | B2 | |
| DK2011888T3 | Denmark | T3 | |
| US7777020B2 | United States of America | B2 |
50 legal events, as 8 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Ep patent expiredExpiredEUP | EUP | DK | |
| Patent ceasedCeasedPL | PL | CH | |
| Discontinued because of reaching the maximum lifetime of a patentV4 | V4 | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Ep patent validated in greeceEP | EP | GR | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| New agentNV | NV | CH | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedNOT ENGLISHFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Title (correction)SYNTHESIS OF PROTEINS OR POLYPEPTIDES ENCODED BY A SEQUENCE OF HIV-1, HIV-2 OR SIV.RTI1 | RTI1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0806484
- Publication, DOCDB
- 0806484
- Publication, EPODOC
- EP0806484
- Application
- 97110543
- Application, DOCDB
- 97110543
- Application, EPODOC
- EP19970110543
Titles3
- German
- Nukleotid-Sequenzen von HIV-1, HIV-2 and SIV Retrovirusgenomen, ihre Verwendung zur Amplifizierung von diesen Retroviren und zur in vitro Diagnostik von diesen Viren verursachten Infektionen
- English
- Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses
- French
- Séquences nucléotidiques issues du genome des rétrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces rétrovirus et pour le diagnostic in vitro des infections dues à ces virus
Classification
- CPC, 10
- C07K14/005
- A61K38/00
- A61K39/00
- C12N2740/15022
- C12N2740/16022
- C12Q1/703
- G01N2333/16
- Y10S435/974
- Y10S435/975
- A61P31/18
- IPC, 15
- A61K39 00
- A61K39 21
- A61K48 00
- A61P31 18
- C07H21 04
- C07K14 00
- C07K14 155
- C07K14 16
- C07K16 00
- C07K16 10
- C12N15 09
- C12N15 49
- C12Q1 68
- C12Q1 70
- G01N33 569
Designated states1
- Contracting states, 1
- Sweden